Pałka Karol, Kubisa Marta, Akbas Anna, Kubisa Michał, Dobrakowski Michał
Medical University of Silesia, Katowice, Poland.
Carolina Medical Center, Warsaw, Poland.
Knee Surg Sports Traumatol Arthrosc. 2025 Jun;33(6):2027-2043. doi: 10.1002/ksa.12495. Epub 2024 Oct 6.
Chondral and osteochondral lesions in the knee are common conditions that significantly impair individuals' well-being and can lead to osteoarthritis, imposing substantial burdens on healthcare systems. The limited natural healing capacity of articular cartilage necessitates innovative treatment strategies. Microfracture (MF) is a widely used technique for knee chondral defects, but its long-term efficacy is often inadequate. Although recent randomised controlled trials have compared microfractures with scaffold-enhanced therapies, a comprehensive systematic review and meta-analysis are lacking.
An extensive literature search was conducted in PubMed and EMBASE databases following PRISMA guidelines. Inclusion criteria focused on randomised controlled trials (RCTs) comparing microfractures alone to matrix-induced chondrogenesis for knee chondral defects with at least a 12-month follow-up. Ten randomised controlled trials conducted between 2013 and 2024, enroling 378 patients, were included.
The meta-analysis showed no significant superiority of scaffolds over MF (p > 0.05) in International Knee Documentation Committee, Knee Injury and Osteoarthritis Outcome, Visual Analog Scale, and Magnetic Resonance Observation of Cartilage Repair Tissue scores at 12 and 24 months. However, individual studies suggested the potential benefits of scaffolds, especially in long-term outcomes. Clinical improvements from MF typically decline after 2-3 years, underscoring the need for long-term follow-up in future research.
Our meta-analysis shows no significant difference between MF and MF with scaffold in treating knee cartilage defects, though some long-term RCTs demonstrate statistically significant differences. The absence of a universally accepted algorithm for analysing knee chondral defects limits this study. Establishing reliable guidelines and standardised study protocols is essential to improve long-term patient outcomes and the quality of future papers.
Level I.
膝关节软骨和骨软骨损伤是常见病症,会严重影响个人健康,并可能导致骨关节炎,给医疗系统带来沉重负担。关节软骨有限的自然愈合能力需要创新的治疗策略。微骨折术(MF)是治疗膝关节软骨缺损广泛使用的技术,但其长期疗效往往欠佳。尽管近期的随机对照试验比较了微骨折术与支架增强疗法,但缺乏全面的系统评价和荟萃分析。
按照PRISMA指南在PubMed和EMBASE数据库中进行广泛的文献检索。纳入标准集中于随机对照试验(RCT),该试验比较单纯微骨折术与基质诱导软骨形成术治疗膝关节软骨缺损,且随访时间至少为12个月。纳入了2013年至2024年间进行的10项随机对照试验,共纳入378例患者。
荟萃分析显示,在12个月和24个月时,国际膝关节文献委员会、膝关节损伤和骨关节炎结局、视觉模拟量表以及软骨修复组织磁共振观察评分方面,支架治疗并不比微骨折术具有显著优势(p>0.05)。然而,个别研究表明支架治疗具有潜在益处,尤其是在长期结局方面。微骨折术带来的临床改善通常在2至3年后下降,这凸显了未来研究中进行长期随访的必要性。
我们的荟萃分析表明,微骨折术与使用支架的微骨折术在治疗膝关节软骨缺损方面无显著差异,尽管一些长期随机对照试验显示存在统计学显著差异。缺乏普遍接受的膝关节软骨缺损分析算法限制了本研究。建立可靠的指南和标准化研究方案对于改善患者长期结局和提高未来论文质量至关重要。
I级